Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

ExpressMD Telemedicine Patient Home Monitor Integrates SunTech Medical Blood Pressure Technology
SunTech Medical, a leading manufacturer of blood pressure monitors and OEM non-invasive blood pressure (OEM NIBP) modules, is pleased to announce the inclusion of their clinical-grade blood pressure technology in ExpressMD"s Electronic House Call™ remote patient monitoring device for telemedicine.

Resolvyx Initiates Phase I Clinical Trial Of Novel Resolvin, RX-10001, For Asthma And Inflammatory Diseases
Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that it has initiated the first human clinical trial evaluating an oral resolvin therapeutic, RX-10001, in a Phase I clinical trial in healthy volunteers. RX-10001 is a synthetic form of RvE1, a naturally occurring resolvin, which in animal studies has been shown to activate the body"s own off-switch mechanisms for inflammation and to promote healing for normal tissue function. In preclinical testing, RX-10001 and analogs have shown high potency across a range of inflammatory disease models, including asthma, colitis, rheumatoid arthritis, and atherosclerosis.
News of the day
Ban Ki-Moon Calls On Governments To Eradicate Polio
U.N. Secretary General Ban Ki-moon on Sunday at the Rotary International (RI) Annual Convention in Birmingham, U.K., said that governments worldwide should continue to work towards eradicating polio, BBC reports. Ban said polio is endemic in four countries - down from 125 countries in 1985 when RI launched its campaign, which has so far raised $250 million to eradicate the disease - BBC writes.
Diagnostics

Endeavor Drug-Eluting Stent Is First To Receive CE Mark For Treating Acute Coronary Syndrome

Medtronic, Inc. (NYSE: MDT), announced that its Endeavor drug-eluting stent (DES) is the first and only coronary stent to have received CE (Conformité Européene) Mark approval for treating patients with acute coronary syndrome (ACS), which includes unstable angina and acute myocardial infarction (AMI), commonly known as heart attack. Medtronic is launching the unique ACS indication for the Endeavor DES today at PCR, a large and prestigious international meeting of interventional cardiologists. At this meeting today, Prof. Martin Rothman of the London Chest Hospital in the U.K. released positive new 12Ò€òmonth data from the international realÒ€òworld registry EÒ€òFive study (n=8,314) that show comparable outcomes for Endeavor DES patients with and without ACS . "Considering the distinctive safety record of the Endeavor stent, this indication for ACS makes perfect sense," said Prof. Rothman. "Results from the EÒ€òFive study support the use of the Endeavor stent in realÒ€òworld clinical practice, including ACS patients." Clinical research shows that ACS patients are at higher risk of stent thrombosis and mortality than nonÒ€òACS patients. ACS is a complex disease state for which drugÒ€òeluting stents are sometimes avoided due to concerns over longÒ€òterm safety and patient compliance with antiplatelet medication. "Of critical importance for safety, the biocompatibility of the Endeavor stent allows rapid and complete healing of the vessel wall," explained Sean Salmon, vice president and general manager of Medtronic CardioVascular"s Coronary and Peripheral business. "We believe that this healthy healing is the key to longÒ€òterm safety and efficacy." The EÒ€òFive study demonstrated no statistically significant difference on the primary endpoint - the rate of major adverse cardiac events (MACE) at one year - between ACS patients (7.8 percent, n=3,973) and nonÒ€òACS patients (7.2 percent, n=4,341). Rates of death, MI and late stent thrombosis (LST) at one year were similarly low and comparable between the two groups. - AllÒ€òcause mortality - 2.7% ACS, 2.2%, nonÒ€òACS - Cardiac death - 2.0% ACS, 1.5% nonÒ€òACS - MI - 1.8% ACS, 1.5% nonÒ€òACS - Cardiac death + MI - 3.4% ACS, 2.7% nonÒ€òACS - LST (ARC def/prob) - 0.5% ACS, 0.3% nonÒ€òACS Low and similar rates of standard efficacy measures were also observed, including target lesion revascularization (TLR), target vessel revascularization (TVR) and target vessel failure (TVF). On all these measures, there were no statistically significant differences between the ACS and nonÒ€òACS groups. Medtronic"s Endeavor stent originally received the CE mark in August 2005 as a treatment for coronary artery disease. This latest approval enables Medtronic to market the Endeavor DES specifically for ACS patients in the European Union, and all other countries that recognize the CE Mark. These countries do not include the United States or Japan, where the Endeavor DES is also commercially available but is not indicated for ACS patients. Medtronic, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009